The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has posted a grant opportunity titled "DoD Bone Marrow Failure, Investigator-Initiated Research Award". This grant aims to support research in the field of bone marrow failure and offers two funding levels with different intents.
Funding Level 1 (FL1) is intended to support studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research and/or patient care in the FY24 BMFRP Focus Areas. FL1 awards may involve translational and clinical research, including studies in animal models, research with human data and/or anatomical substances, and research with human subjects. However, FL1 awards may not be used to support a clinical trial. Multidisciplinary collaborations are encouraged.
Funding Level 2 (FL2) is aimed at supporting Investigational New Drug (IND) application-enabling efforts. The BMFRP recognizes the challenges associated with advancing promising therapeutic agents from the laboratory to clinical evaluation. FL2 awards require empirical studies focused on the accumulation of data for a lead therapeutic candidate that will be included in an IND application submission to the U.S. Food and Drug Administration (FDA). FL2 applications must address the FY24 BMFRP Focus Area of finding effective treatments and cures for bone marrow failure.
The grant opportunity does not require cost sharing or matching and is open to unrestricted applicants. The total program funding is $2,440,000, and it is expected that two awards will be granted. The closing date for applications is October 9, 2024, and the archive date is November 8, 2024.
For more information and assistance, interested applicants can contact the CDMRP Help Desk via phone at 301-682-5507 or email at help@eBRAP.org.